| Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
06/30/2021 |
64764030020 |
Entyvio 300mg 20mL Vial |
04/01/2021 |
279.87 |
7276.63 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000232 |
TerSera Therapeutics LLC |
03/31/2021 |
70720072010 |
PRIALT Intrathecal Solution 100mcg/1mL, 1ML Vial, Qty 1 |
01/04/2021 |
53.04 |
936.99 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC. |
744.98 |
716.05 |
2004 |
608.33 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
| Rx0000232 |
TerSera Therapeutics LLC |
09/30/2021 |
70720072010 |
PRIALT Intrathecal Solution 100mcg/1mL, 1ML Vial, Qty 1 |
07/01/2021 |
56.22 |
993.21 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC |
744.98 |
716.05 |
2004 |
608.33 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available |
| Rx0000232 |
TerSera Therapeutics LLC |
03/31/2021 |
70720072310 |
PRIALT Intrathecal Solution 500mcg/20mL, 20ML Vial, Qty 1 |
01/04/2021 |
174.30 |
4531.80 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC. |
3724.90 |
3580.25 |
2004 |
3041.67 |
None |
TerSera NDC first launched on 10/09/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
| Rx0000232 |
TerSera Therapeutics LLC |
09/30/2021 |
70720072310 |
PRIALT Intrathecal Solution 500mcg/20mL, 20ML Vial, Qty 1 |
07/01/2021 |
181.27 |
4713.07 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC |
3724.90 |
3580.25 |
2004 |
3041.67 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available |
| Rx0000232 |
TerSera Therapeutics LLC |
03/31/2021 |
70720072210 |
PRIALT Intrathecal Solution 500mcg/5mL, 5ML Vial, Qty 1 |
01/04/2021 |
174.30 |
4531.80 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC. |
3724.90 |
3580.25 |
2004 |
3041.67 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
| Rx0000232 |
TerSera Therapeutics LLC |
09/30/2021 |
70720072210 |
PRIALT Intrathecal Solution 500mcg/5mL, 5ML Vial, Qty 1 |
07/01/2021 |
181.27 |
4713.07 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC |
3724.90 |
3580.25 |
2004 |
3041.67 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available |
| Rx0000232 |
TerSera Therapeutics LLC |
06/30/2021 |
70183012584 |
XERMELO (telostristat ethyl), Oral Tablet, 250mg, 1 Case/84 Tablets |
04/01/2021 |
353.21 |
7561.55 |
02/27/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/08/2020 |
Lexicon Pharmaceuticals, Inc |
160000000 |
None |
Lexicon received approximately $160M in upfront payments and up to $65 million in future milestone payments plus mid-teens royalties on net sales of XERMELO for the treatment of biliary tract cancer. |
6559.00 |
5961.00 |
2017 |
5164.00 |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
| Rx0000232 |
TerSera Therapeutics LLC |
09/30/2021 |
70720095036 |
ZOLADEX (Goserelin Acetate), Implant, 3.6mg, 1 Syringe |
07/01/2021 |
48.87 |
747.01 |
04/13/2022 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
04/06/2018 |
AztraZeneca |
320000000 |
None |
AstraZeneca received a $250m upfront payment for the rights of Zoladex, with double-digit quarterly sales-based payments being recieved on an ongoing basis. A further $70m was also in the sell should Zoladex meet a series of sales-related milestones |
605.00 |
550.50 |
2003 |
375.99 |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2021 |
68546017260 |
AUSTEDO TABLETS 12MG 60 |
01/01/2021 |
342.33 |
6144.53 |
03/07/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2021 |
68546017060 |
AUSTEDO TABLETS 6MG 60 |
01/01/2021 |
228.20 |
4096.30 |
03/07/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2021 |
68546017160 |
AUSTEDO TABLETS 9MG 60 |
01/01/2021 |
256.70 |
4608.30 |
03/07/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2021 |
68546014256 |
AZILECT TABLETS 0.5MG 30 |
01/01/2021 |
78.30 |
910.90 |
08/27/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2021 |
68546022956 |
AZILECT TABLETS 1MG 30 |
01/01/2021 |
78.30 |
910.90 |
08/27/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459051230 |
ACTIQ BKU 1200MCG 1CTNX30 US |
01/01/2021 |
491.40 |
5718.80 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459051201 |
ACTIQ BKU 1200MCG 1CTNX30 US IP |
01/01/2021 |
16.40 |
190.63 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0512-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459051630 |
ACTIQ BKU 1600MCG 1CTNX30 US |
01/01/2021 |
606.20 |
7054.90 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459051601 |
ACTIQ BKU 1600MCG 1CTNX30 US IP |
01/01/2021 |
20.20 |
235.16 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0516-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050230 |
ACTIQ BKU 200MCG 1CTNX30 US |
01/01/2021 |
205.90 |
2396.30 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050201 |
ACTIQ BKU 200MCG 1CTNX30 US IP |
01/01/2021 |
6.90 |
79.88 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0502-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050430 |
ACTIQ BKU 400MCG 1CTNX30 US |
01/01/2021 |
260.60 |
3032.90 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050401 |
ACTIQ BKU 400MCG 1CTNX30 US IP |
01/01/2021 |
8.70 |
101.10 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0504-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050630 |
ACTIQ BKU 600MCG 1CTNX30 US |
01/01/2021 |
319.40 |
3717.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050601 |
ACTIQ BKU 600MCG 1CTNX30 US IP |
01/01/2021 |
10.60 |
123.90 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0506-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050830 |
ACTIQ BKU 800MCG 1CTNX30 US |
01/01/2021 |
378.00 |
4399.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050801 |
ACTIQ BKU 800MCG 1CTNX30 US IP |
01/01/2021 |
12.60 |
146.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0508-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844011001 |
ADDERALL(R) TABLETS 10MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844011201 |
ADDERALL(R) TABLETS 12.5MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844011501 |
ADDERALL(R) TABLETS 15MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844012001 |
ADDERALL(R) TABLETS 20MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844013001 |
ADDERALL(R) TABLETS 30MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844010501 |
ADDERALL(R) TABLETS 5MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844011701 |
ADDERALL(R) TABLETS 7.5MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459070060 |
AMRIX CAP 15 MG 1BT X60 |
01/01/2021 |
238.30 |
2773.80 |
02/26/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459070160 |
AMRIX CAP 30 MG 1BTLX60 |
01/01/2021 |
238.30 |
2773.80 |
02/26/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054128 |
FENTORA TB 100MCG 1CTNX28 US |
01/01/2021 |
150.70 |
1754.00 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054104 |
FENTORA TB 100MCG 1CTNX28 US IP |
01/01/2021 |
5.40 |
62.64 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0541-28, which has separately been reported above/below. Because the multi-pack container is comprised of twenty-eight single packs, and so the WAC numbers reported here for the single pack are 1/28th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054228 |
FENTORA TB 200MCG 1CTNX28 US |
01/01/2021 |
190.40 |
2216.10 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054204 |
FENTORA TB 200MCG 1CTNX28 US IP |
01/01/2021 |
6.80 |
79.15 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0542-28, which has separately been reported above/below. Because the multi-pack container is comprised of twenty-eight single packs, and so the WAC numbers reported here for the single pack are 1/28th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054428 |
FENTORA TB 400MCG 1CTNX28 US |
01/01/2021 |
276.30 |
3215.50 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054404 |
FENTORA TB 400MCG 1CTNX28 US IP |
01/01/2021 |
9.90 |
114.84 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0544-28, which has separately been reported above/below. Because the multi-pack container is comprised of twenty-eight single packs, and so the WAC numbers reported here for the single pack are 1/28th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054628 |
FENTORA TB 600MCG 1CTNX28 US |
01/01/2021 |
358.70 |
4174.60 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054604 |
FENTORA TB 600MCG 1CTNX28 US IP |
01/01/2021 |
12.80 |
149.09 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0546-28, which has separately been reported above/below. Because the multi-pack container is comprised of twenty-eight single packs, and so the WAC numbers reported here for the single pack are 1/28th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054828 |
FENTORA TB 800MCG 1CTNX28 US |
01/01/2021 |
441.90 |
5143.00 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054804 |
FENTORA TB 800MCG 1CTNX28 US IP |
01/01/2021 |
15.80 |
183.68 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0548-28, which has separately been reported above/below. Because the multi-pack container is comprised of twenthy-eight single packs, and so the WAC numbers reported here for the single pack are 1/28th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
52544008001 |
FIORICET 50/300/40MG CAPSULES 100 |
01/01/2021 |
51.20 |
596.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/02/2016 |
Watson/Actavis |
None |
None |
Teva acquired this particular product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price; as a result, there was no one particular price that Teva paid to acquire the rights to this product. We were, nonetheless, required to enter a non-zero value in the "Acquisition Price" field, and so we entered $33,430,000,000, which is the total amount that Teva paid (along with roughly 100 million shares of Teva stock) in connection with the broader deal referenced above. Once again, and to be clear, this total is not representative of the amount that Teva paid for the rights to this product in particular. |
449.93 |
None |
2013 |
227.00 |
None |
No patent expiration date listed - no patents ever listed |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
52544008201 |
FIORICET/CODEINE 50/300/40/30MG CAPS 100 |
01/01/2021 |
107.20 |
1247.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/02/2016 |
Watson/Actavis |
None |
None |
Teva acquired this particular product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price; as a result, there was no one particular price that Teva paid to acquire the rights to this product. We were, nonetheless, required to enter a non-zero value in the "Acquisition Price" field, and so we entered $33,430,000,000, which is the total amount that Teva paid (along with roughly 100 million shares of Teva stock) in connection with the broader deal referenced above. Once again, and to be clear, this total is not representative of the amount that Teva paid for the rights to this product in particular. |
942.09 |
None |
2013 |
475.00 |
None |
No patent expiration date listed - no patents ever listed |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459041230 |
GABITRIL TAB 12MG 1BTLX30 |
01/01/2021 |
36.30 |
422.20 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459041630 |
GABITRIL TAB 16MG 1BTLX30 |
01/01/2021 |
47.50 |
552.80 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459040230 |
GABITRIL TAB 2MG 1BTLX30 |
01/01/2021 |
28.10 |
326.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459040430 |
GABITRIL TAB 4MG 1BTLX30 |
01/01/2021 |
28.10 |
326.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459021530 |
NUVIGIL TAB 150MG 1BTLX30 |
01/01/2021 |
79.60 |
926.40 |
06/18/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459022030 |
NUVIGIL TAB 200MG 1BTLX30 |
01/01/2021 |
79.60 |
926.40 |
06/18/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459022530 |
NUVIGIL TAB 250MG 1BTLX30 |
01/01/2021 |
79.60 |
926.40 |
06/18/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459020530 |
NUVIGIL TAB 50MG 1BTLX30 |
01/01/2021 |
26.50 |
307.90 |
06/18/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459010130 |
PROVIGIL TAB 100MG 1BTLX30 |
01/01/2021 |
111.40 |
1296.40 |
05/29/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459020130 |
PROVIGIL TAB 200MG 1BTLX30 |
01/01/2021 |
168.30 |
1958.80 |
05/29/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000218 |
Teva Respiratory, LLC |
06/30/2021 |
59310057922 |
PROAIR INH AERO 90MCG 1INH 200 |
06/01/2021 |
3.95 |
70.83 |
01/01/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; Teva developed and launched the product. |
| Rx0000218 |
Teva Respiratory, LLC |
06/30/2021 |
59310058020 |
PROAIR RESPICLICK 200 DOSE-117 |
06/01/2021 |
3.69 |
66.21 |
01/13/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; Teva developed and launched the product. |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2021 |
59310040606 |
QNASL PLV INHALER 40MCG 60/ACT TRADE |
01/01/2021 |
14.35 |
257.52 |
10/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2021 |
59310041012 |
QNASL PLV INHALER 80MCG 120/ACT TRADE |
01/01/2021 |
14.35 |
257.52 |
10/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2021 |
59310030240 |
QVAR BA INHALER 40MCG 120/ACT |
01/01/2021 |
9.51 |
199.72 |
01/25/2039 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2021 |
59310030480 |
QVAR BA INHALER 80MCG 120/ACT |
01/01/2021 |
12.73 |
267.41 |
01/25/2039 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285052302 |
ANTABUSE TABLETS 250MG 100 |
01/01/2021 |
82.40 |
959.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285052402 |
ANTABUSE TABLETS 500MG 100 |
01/01/2021 |
131.90 |
1535.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285042410 |
AYGESTIN(R) TABLETS 5MG 50 |
01/01/2021 |
23.80 |
277.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285013197 |
LOESTRIN (R) 21 TABLETS 1.0MG/20MCG 105 |
01/01/2021 |
66.10 |
769.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285012797 |
LOESTRIN (R) 21 TABLETS 1.5MG/30MCG 105 |
01/01/2021 |
66.10 |
769.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285012570 |
LOESTRIN (R) FE 28 TAB 1MG/20MCG 140 |
01/01/2021 |
66.10 |
769.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285012870 |
LOESTRIN (R) FE 28 TABLETS 1.5MG/30MCG 140 |
01/01/2021 |
66.10 |
769.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285009287 |
LOSEASONIQUE™ TAB 182 |
01/01/2021 |
76.90 |
895.10 |
12/05/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285012058 |
MIRCETTE 28 TABLETS .15MG/.02MG .01MG |
01/01/2021 |
82.90 |
964.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285006390 |
PREFEST(R) TABLETS 180 |
01/01/2021 |
84.40 |
982.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285043187 |
QUARTETTE (TM) TAB 182 |
01/01/2021 |
92.10 |
1071.90 |
03/11/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285043165 |
QUARTETTE (TM) TAB 91 |
01/01/2021 |
46.10 |
535.95 |
03/11/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 51285-0431-87, which has separately been reported above/below. Because the multi-pack container is comprised of two single packs, the WAC numbers reported here for the single pack are half of the multi-pack’s WAC numbers. Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285008787 |
SEASONIQUE(TM) TAB 182 |
01/01/2021 |
76.90 |
895.10 |
12/05/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285004001 |
ZIAC(R) TABLETS 10MG/6.25MG 30 |
01/01/2021 |
19.40 |
225.80 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285004702 |
ZIAC(R) TABLETS 2.5MG/6.25MG 100 |
01/01/2021 |
64.70 |
752.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285005002 |
ZIAC(R) TABLETS 5MG/6.25MG 100 |
01/01/2021 |
64.70 |
752.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000183 |
Tris Pharma, Inc |
03/31/2021 |
27808010201 |
Dyanavel XR 2.5mg/mL Extended-Release Suspension |
01/04/2021 |
73.66 |
1303.45 |
None |
Single Source Drug |
None |
1 |
Increased operational costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |